Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 331

1.

Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases - potentially novel therapeutic targets.

Ito Y, Hart JR, Vogt PK.

Expert Opin Ther Targets. 2018 Oct;22(10):869-877. doi: 10.1080/14728222.2018.1522302. Epub 2018 Sep 24.

PMID:
30205700
2.

Synthetic molecules for disruption of the MYC protein-protein interface.

Jacob NT, Miranda PO, Shirey RJ, Gautam R, Zhou B, de Orbe Izquierdo ME, Hixon MS, Hart JR, Ueno L, Vogt PK, Janda KD.

Bioorg Med Chem. 2018 Aug 7;26(14):4234-4239. doi: 10.1016/j.bmc.2018.07.019. Epub 2018 Jul 11.

PMID:
30037753
3.

Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β.

Ito Y, Vogt PK, Hart JR.

Oncotarget. 2017 Aug 3;8(34):55863-55876. doi: 10.18632/oncotarget.19866. eCollection 2017 Aug 22.

4.

tsRNA signatures in cancer.

Balatti V, Nigita G, Veneziano D, Drusco A, Stein GS, Messier TL, Farina NH, Lian JB, Tomasello L, Liu CG, Palamarchuk A, Hart JR, Bell C, Carosi M, Pescarmona E, Perracchio L, Diodoro M, Russo A, Antenucci A, Visca P, Ciardi A, Harris CC, Vogt PK, Pekarsky Y, Croce CM.

Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8071-8076. doi: 10.1073/pnas.1706908114. Epub 2017 Jul 10.

5.

A butterfly effect in cancer.

Vogt PK, Hart JR, Yates JR 3rd.

Mol Cell Oncol. 2015 Apr 14;3(1):e1029063. doi: 10.1080/23723556.2015.1029063. eCollection 2016 Jan.

6.

A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.

Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K, Baker SJ, Cosenza SC, Basu I, Gupta YK, Reddy MV, Ueno L, Hart JR, Vogt PK, Mulholland D, Guha C, Aggarwal AK, Reddy EP.

Cell. 2016 Apr 21;165(3):643-55. doi: 10.1016/j.cell.2016.03.045.

7.

MINCR is not a MYC-induced lncRNA.

Hart JR, Weinberg MS, Morris KV, Roberts TC, Janda KD, Garner AL, Vogt PK.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):E496-7. doi: 10.1073/pnas.1519903113. Epub 2016 Jan 25. No abstract available.

8.

RICHARD BING: 12 OCTOBER 1909 - 8 NOVEMBER 2010.

Vogt PK.

Proc Am Philos Soc. 2014 Sep;158(3):287-91. No abstract available.

PMID:
26390751
9.

ProteinInferencer: Confident protein identification and multiple experiment comparison for large scale proteomics projects.

Zhang Y, Xu T, Shan B, Hart J, Aslanian A, Han X, Zong N, Li H, Choi H, Wang D, Acharya L, Du L, Vogt PK, Ping P, Yates JR 3rd.

J Proteomics. 2015 Nov 3;129:25-32. doi: 10.1016/j.jprot.2015.07.006. Epub 2015 Jul 18.

10.

A brave new MYC-amplified world.

Weinberg MS, Hart JR, Vogt PK.

Aging (Albany NY). 2015 Jul;7(7):459-60. No abstract available.

11.

Quantification of nascent transcription by bromouridine immunocapture nuclear run-on RT-qPCR.

Roberts TC, Hart JR, Kaikkonen MU, Weinberg MS, Vogt PK, Morris KV.

Nat Protoc. 2015 Aug;10(8):1198-211. doi: 10.1038/nprot.2015.076. Epub 2015 Jul 16.

12.

MYCNOS functions as an antisense RNA regulating MYCN.

Vadie N, Saayman S, Lenox A, Ackley A, Clemson M, Burdach J, Hart J, Vogt PK, Morris KV.

RNA Biol. 2015;12(8):893-9. doi: 10.1080/15476286.2015.1063773.

13.

MYC regulates the non-coding transcriptome.

Hart JR, Roberts TC, Weinberg MS, Morris KV, Vogt PK.

Oncotarget. 2014 Dec 30;5(24):12543-54.

14.

The butterfly effect in cancer: a single base mutation can remodel the cell.

Hart JR, Zhang Y, Liao L, Ueno L, Du L, Jonkers M, Yates JR 3rd, Vogt PK.

Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1131-6. doi: 10.1073/pnas.1424012112. Epub 2015 Jan 12.

15.

Oncogenic activity of the regulatory subunit p85β of phosphatidylinositol 3-kinase (PI3K).

Ito Y, Hart JR, Ueno L, Vogt PK.

Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16826-9. doi: 10.1073/pnas.1420281111. Epub 2014 Nov 10.

16.

In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential.

Raffeiner P, Röck R, Schraffl A, Hartl M, Hart JR, Janda KD, Vogt PK, Stefan E, Bister K.

Oncotarget. 2014 Oct 15;5(19):8869-78.

17.

Inhibitor of MYC identified in a Kröhnke pyridine library.

Hart JR, Garner AL, Yu J, Ito Y, Sun M, Ueno L, Rhee JK, Baksh MM, Stefan E, Hartl M, Bister K, Vogt PK, Janda KD.

Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12556-61. doi: 10.1073/pnas.1319488111. Epub 2014 Aug 11.

18.

MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer.

Valeri N, Braconi C, Gasparini P, Murgia C, Lampis A, Paulus-Hock V, Hart JR, Ueno L, Grivennikov SI, Lovat F, Paone A, Cascione L, Sumani KM, Veronese A, Fabbri M, Carasi S, Alder H, Lanza G, Gafa' R, Moyer MP, Ridgway RA, Cordero J, Nuovo GJ, Frankel WL, Rugge M, Fassan M, Groden J, Vogt PK, Karin M, Sansom OJ, Croce CM.

Cancer Cell. 2014 Apr 14;25(4):469-83. doi: 10.1016/j.ccr.2014.03.006.

19.

An Algorithm for Generating Small RNAs Capable of Epigenetically Modulating Transcriptional Gene Silencing and Activation in Human Cells.

Ackley A, Lenox A, Stapleton K, Knowling S, Lu T, Sabir KS, Vogt PK, Morris KV.

Mol Ther Nucleic Acids. 2013 Jul 9;2:e104. doi: 10.1038/mtna.2013.33.

20.

Retroviral oncogenes: a historical primer.

Vogt PK.

Nat Rev Cancer. 2012 Sep;12(9):639-48. doi: 10.1038/nrc3320. Epub 2012 Aug 17. Review.

21.

Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence.

Kolesnichenko M, Hong L, Liao R, Vogt PK, Sun P.

Cell Cycle. 2012 Jun 15;11(12):2391-401. doi: 10.4161/cc.20683. Epub 2012 Jun 15.

22.

PI3K and STAT3: a new alliance.

Vogt PK, Hart JR.

Cancer Discov. 2011 Nov;1(6):481-6. doi: 10.1158/2159-8290.CD-11-0218. Review.

23.

Progress in breast cancer research.

Polyak K, Vogt PK.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2715-7. doi: 10.1073/pnas.1201091109. Epub 2012 Feb 13. No abstract available.

24.

100 years of Rous sarcoma virus.

Weiss RA, Vogt PK.

J Exp Med. 2011 Nov 21;208(12):2351-5. doi: 10.1084/jem.20112160.

25.

Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase.

Sun M, Hart JR, Hillmann P, Gymnopoulos M, Vogt PK.

Cell Cycle. 2011 Nov 1;10(21):3731-9. doi: 10.4161/cc.10.21.17920. Epub 2011 Nov 1.

26.

Essential role of Stat3 in PI3K-induced oncogenic transformation.

Hart JR, Liao L, Yates JR 3rd, Vogt PK.

Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13247-52. doi: 10.1073/pnas.1110486108. Epub 2011 Jul 25.

27.

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.

Yuan J, Mehta PP, Yin MJ, Sun S, Zou A, Chen J, Rafidi K, Feng Z, Nickel J, Engebretsen J, Hallin J, Blasina A, Zhang E, Nguyen L, Sun M, Vogt PK, McHarg A, Cheng H, Christensen JG, Kan JL, Bagrodia S.

Mol Cancer Ther. 2011 Nov;10(11):2189-99. doi: 10.1158/1535-7163.MCT-11-0185. Epub 2011 Jul 12.

28.

Phosphorylation of AKT: a mutational analysis.

Hart JR, Vogt PK.

Oncotarget. 2011 Jun;2(6):467-76.

29.

Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactions.

Whitby LR, Ando Y, Setola V, Vogt PK, Roth BL, Boger DL.

J Am Chem Soc. 2011 Jul 6;133(26):10184-94. doi: 10.1021/ja201878v. Epub 2011 Jun 15.

30.

Historical Introduction to the General Properties of Retroviruses.

Vogt PK.

In: Coffin JM, Hughes SH, Varmus HE, editors. Retroviruses. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1997. No abstract available.

31.

PI3K p110β: more tightly controlled or constitutively active?

Vogt PK.

Mol Cell. 2011 Mar 4;41(5):499-501. doi: 10.1016/j.molcel.2011.02.017. No abstract available.

32.
34.

Cell entry by non-enveloped viruses.

Johnson JE, Vogt PK.

Curr Top Microbiol Immunol. 2010;343:v-vii. No abstract available.

PMID:
21166102
35.

Therapeutic Targeting of Myc.

Prochownik EV, Vogt PK.

Genes Cancer. 2010 Jun;1(6):650-659.

36.

Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.

Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15547-52. doi: 10.1073/pnas.1009652107. Epub 2010 Aug 16.

38.

Phosphatidylinositol 3-kinase: the oncoprotein.

Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, Zhao L, Denley A.

Curr Top Microbiol Immunol. 2010;347:79-104. doi: 10.1007/82_2010_80. Review.

39.

Long antisense non-coding RNAs and their role in transcription and oncogenesis.

Morris KV, Vogt PK.

Cell Cycle. 2010 Jul 1;9(13):2544-7. doi: 10.4161/cc.9.13.12145. Review.

40.

PI3K: from the bench to the clinic and back.

Vanhaesebroeck B, Vogt PK, Rommel C.

Curr Top Microbiol Immunol. 2010;347:1-19. doi: 10.1007/82_2010_65. Review.

41.

Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF.

Murphy EA, Shields DJ, Stoletov K, Dneprovskaia E, McElroy M, Greenberg JI, Lindquist J, Acevedo LM, Anand S, Majeti BK, Tsigelny I, Saldanha A, Walsh B, Hoffman RM, Bouvet M, Klemke RL, Vogt PK, Arnold L, Wrasidlo W, Cheresh DA.

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4299-304. doi: 10.1073/pnas.0909299107. Epub 2010 Feb 12.

42.

Oncogenes and the revolution in cancer research: homage to hidesaburo hanafusa (1929-2009).

Vogt PK.

Genes Cancer. 2010 Jan;1(1):6-11. doi: 10.1177/1947601909356102. No abstract available.

44.

Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic.

Dannemann N, Hart JR, Ueno L, Vogt PK.

Int J Cancer. 2010 Jul 1;127(1):239-44. doi: 10.1002/ijc.25012. Erratum in: Int J Cancer. 2012 Jun 15;130(12):E3. Int J Cancer. 2012 Apr 15;130(8):1970.

45.

Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation.

Shi J, Stover JS, Whitby LR, Vogt PK, Boger DL.

Bioorg Med Chem Lett. 2009 Nov 1;19(21):6038-41. doi: 10.1016/j.bmcl.2009.09.044. Epub 2009 Sep 17.

46.

Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt.

Bai D, Ueno L, Vogt PK.

Int J Cancer. 2009 Dec 15;125(12):2863-70. doi: 10.1002/ijc.24748.

47.

Requirement of phosphatidylinositol(3,4,5)trisphosphate in phosphatidylinositol 3-kinase-induced oncogenic transformation.

Denley A, Gymnopoulos M, Kang S, Mitchell C, Vogt PK.

Mol Cancer Res. 2009 Jul;7(7):1132-8. doi: 10.1158/1541-7786.MCR-09-0068. Epub 2009 Jul 7.

48.

Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function.

Jiang H, Bower KE, Beuscher AE 4th, Zhou B, Bobkov AA, Olson AJ, Vogt PK.

Mol Pharmacol. 2009 Sep;76(3):491-502. doi: 10.1124/mol.109.054858. Epub 2009 Jun 4.

49.

Posttranslational regulation of Myc by promyelocytic leukemia zinc finger protein.

Shi J, Vogt PK.

Int J Cancer. 2009 Oct 1;125(7):1558-65. doi: 10.1002/ijc.24449.

50.

Akt demoted in glioblastoma.

Vogt PK, Hart JR.

Sci Signal. 2009 Apr 21;2(67):pe26. doi: 10.1126/scisignal.267pe26.

PMID:
19383977

Supplemental Content

Support Center